Literature DB >> 9577479

Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures.

A Baur1, A Stäbler, R Brüning, R Bartl, A Krödel, M Reiser, M Deimling.   

Abstract

PURPOSE: To evaluate the usefulness of diffusion-weighted magnetic resonance (MR) imaging of bone marrow for differentiating between benign and pathologic vertebral compression fractures.
MATERIALS AND METHODS: Thirty patients with 39 vertebral compression fractures were examined with MR imaging. Diffusion-weighted MR imaging was performed with a steady-state free precession sequence in 22 acute benign osteoporotic and/or traumatic fractures and 17 pathologic compression fractures. Biplanar radiographs, T1-weighted spin-echo (SE) MR images, and short inversion time inversion-recovery (STIR) MR images were available for all patients. The signal intensity characteristics were analyzed qualitatively and quantitatively (bone marrow contrast ratios and signal-to-noise ratios) for all sequences.
RESULTS: At diffusion-weighted MR imaging, all benign vertebral compression fractures were hypo- to isointense to adjacent normal vertebral bodies. Pathologic compression fractures were hyperintense to normal vertebral bodies. Benign vertebral fractures had negative bone marrow contrast ratios at diffusion-weighted imaging, whereas pathologic vertebral fractures had positive values (P < .001). The difference in bone marrow contrast ratios for benign and pathologic compression fractures at T1-weighted SE and STIR imaging was not significant (P > .01).
CONCLUSION: Diffusion-weighted MR imaging provided excellent distinction between pathologic and benign vertebral compression fractures.

Entities:  

Mesh:

Year:  1998        PMID: 9577479     DOI: 10.1148/radiology.207.2.9577479

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  97 in total

1.  Diffusion-weighted imaging of acute vertebral compressions: specific diagnosis of benign versus malignant pathologic fractures.

Authors:  D A Finelli
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

2.  Diffusion-weighted imaging in the distinction of benign from metastatic vertebral compression fractures: is this a numbers game?

Authors:  Steven Falcone
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

3.  Diffusion-weighted imaging in a patient with vertebral and epidural abscesses.

Authors:  James D Eastwood; Robin T Vollmer; James M Provenzale
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

4.  Navigator motion correction of diffusion weighted 3D SSFP imaging.

Authors:  E Bosak; P R Harvey
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.310

5.  Diffusion-weighted imaging of the spine: is it reliable?

Authors:  Mauricio Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2003 Jun-Jul       Impact factor: 3.825

6.  In re: characterization of benign and metastatic vertebral compression fractures with quantitative diffusion MR imaging.

Authors:  Robert V Mulkern; Richard B Schwartz
Journal:  AJNR Am J Neuroradiol       Date:  2003-08       Impact factor: 3.825

7.  Subacute combined degeneration revealed by diffusion-weighted imaging: a case study.

Authors:  E Y Kim; S Y Lee; S H Cha; K S Yi; B S Cho; M H Kang
Journal:  Clin Neuroradiol       Date:  2012-06-16       Impact factor: 3.649

Review 8.  Whole-body MR imaging, bone diffusion imaging: how and why?

Authors:  Diego Jaramillo
Journal:  Pediatr Radiol       Date:  2010-04-30

Review 9.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

Review 10.  Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques.

Authors:  Laura M Fayad; Michael A Jacobs; Xin Wang; John A Carrino; David A Bluemke
Journal:  Radiology       Date:  2012-11       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.